



Bulletin from the Extraordinary General Meeting in Senzime AB (publ) – resolution on new issue of shares with pre-emption rights for existing shareholders

Uppsala, March 3, 2017

The shareholders of Senzime have at the Extraordinary General Meeting on March 3, 2017 resolved, in accordance with the board's proposal, to issue new shares with pre-emption rights for existing shareholders

Motive for the rights issue

The motive for the now resolved rights issue, totaling approximately 24.4 MSEK before issue costs, is to enable the commercialization of Senzime's products and to strengthen the company's financial position. The company is also planning to implement a listing change from AktieTorget to Nasdaq First North during the first half of 2017.

Subscription commitments and guarantee undertakings corresponding to the entire issue amount have been received.

A prospectus, which currently is under examination for approval and registration with the Swedish Financial Supervisory Agency (the "SFSA"), will when the SFSA has approved and registered the prospectus, be available on the company's website www.senzime.com.

Summary of the rights issue terms

New issue of shares with pre-emption rights for existing shareholders

The company's share capital will increase with not more than 565,198 SEK by a new issue of shares with pre-emption rights for existing shareholders.

Number of shares

Not more than 4,521,581 new shares.

Pre-emption rights

Each existing share in Senzime held on the record date entitles to one (1) subscription right and eight (8) subscription rights entitle the holder to subscribe for one (1) new share with pre-emption rights. Additionally, there is an opportunity to subscribe for shares without pre-emption rights.

In the event that all new shares are not subscribed for with subscription rights, shares will *firstly* be allotted to subscribers that have used subscription rights in the issue (in case of oversubscription, pro rata in relation to the number of subscription rights that each subscriber has used to subscribe for new shares), *secondly* to those who have applied for subscription without subscription rights (in case of oversubscription, pro rata in relation to the number of shares set forth in the application), and *thirdly* to the guarantors of the rights issue pro rata in relation to the guaranteed amounts.

Subscription price

The subscription price in the rights issue is 5.40 SEK per share.

Indicative timetable

The record date for participation in the rights issue

March 10, 2017.

The last day for trading in shares *including* subscription rights

March 8, 2017.

First day for trading in shares *excluding* subscription rights

March 9, 2017.

Subscription period

March 14, 2017 – March 28, 2017.

Trading in subscription rights

March 14, 2017 – March 24, 2017.

Subscription commitments and guarantee agreements

The company has received subscription commitments from existing shareholders totaling 7,643,543.40 SEK, corresponding to approximately 31.3 percent of the rights issue, and guarantee undertakings from a guarantee consortium composed of the company's main shareholders totaling 16,772,994.00 SEK, corresponding to approximately 68.7 percent of the rights issue, which means that the company has received subscription commitments and guarantee undertakings totaling 24 416 537.40 SEK, corresponding to 100 percent of the rights issue.

Important information

The information in this press release is not an offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Sensime, neither from Sensime or from anyone else. The invitation to subscribe for shares in Sensime to the persons concerned will only be made through the prospectus

that Senszime intends to publish, inter alia, on the company's website, upon approval and registration by the SFSA. The prospectus will inter alia include risk factors, financial information and information about the company's board of directors. This press release has not been approved by any regulatory authority, and is not a prospectus. Investors should not subscribe for or purchase any securities referred to in this press release except on the basis of the information that will be included in the prospectus that will be published.

Neither the prospectus or this document may be released, published or distributed in the United States, Canada, Australia, Hong Kong, Japan, New Zealand or South Africa or any other country or any jurisdiction where such action or the offer requires registration or measures other than those under Swedish law.

For further information, please contact:

Lena Söderström, CEO of Senszime

Tel: 0708-16 39 12, email: lena.soderstrom@senzime.com.

The information in this press release is information which Senszime AB (publ) is obliged to publish under the EU Market Abuse Regulation No 596/2014. The information was submitted for publication through the agency of the contact person set out above, on March 3, 2017.

TO THE EDITORS

About Senszime

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function preoperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senszime operates in growing markets that in Europe and the United States are valued in excess of \$10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) www.senzime.com.